Ambosol Injection

Adult dosage

Generally, 500 mL is administered by slow intravenous infusion. Typically, a standard infusion rate for adults is over 180 minutes for 500 mL. When administered through a central vein, 500 mL is mixed with carbohydrate solutions and continuously infused over 24 hours into the central vein. Adjustments are made based on age, symptoms, and body weight.

This medication should only be used as directed by a physician. It should not be administered to patients with severe renal impairment, patients with hyperammonemia, patients with amino acid metabolism disorders unrelated to liver dysfunction, patients with metabolic disorders that interfere with nitrogen utilization, patients with cachectic heart failure, patients with pulmonary edema, patients with oliguria or anuria, patients with hypernatremia and hyperchloremia or alkalosis, patients with complete heart block or myasthenia gravis, and patients in a state of fluid overload. Patients with severe acidosis, congestive heart failure or severe heart failure, patients with edema due to sodium retention, patients with hyperkalemia or potassium retention, and patients with renal impairment should be monitored closely during administration. This medication contains sodium bisulfite, which can cause allergic reactions or asthma attacks; therefore, asthmatic patients or those sensitive to sulfites should be especially cautious. During administration, rare hypersensitivity reactions such as rashes may occur, and symptoms such as nausea, vomiting, chest discomfort, palpitations, rapid heartbeat, and elevated blood pressure may present. If administered in large volumes or at a rapid rate, acidosis may occur, leading to chills, fever, headache, dyspnea, and in severe cases, respiratory arrest or shock. If magnesium ions are present, peripheral vasodilation may occur. There may also be a risk of metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, hypoglycemia, elevated liver enzymes, vitamin imbalance, and electrolyte imbalance, requiring caution. Patients with reduced liver or kidney function may experience elevated blood urea nitrogen (BUN) levels and those with liver failure are at risk of amino acid imbalance or coma. Electrolyte balance should be maintained during administration of this medication, and especially during large doses, electrolyte levels should be monitored frequently. Patients with kidney disease, lung disease, or severe heart disease should avoid excessive fluid administration. Diabetic patients should monitor and manage blood glucose levels frequently. This medication may interact with other drugs, so caution is advised when used with tetracycline, calcium salts, or vitamin B1. Safety in pregnant women has not been established, so the medication should only be administered when the therapeutic benefit outweighs the risks. Pediatric patients may have immature liver function; therefore, dosages should be kept low, and blood ammonia levels should be checked frequently. Elderly patients may have reduced body function, so dosage should be administered slowly and adjusted accordingly. Because this medication contains electrolytes, it should be administered slowly to avoid potential side effects from rapid infusion. Injections should be prepared in an aseptic manner, and storage should ensure there are no discolorations or leaks, with clarity checked before use. This medication should not be administered to patients with a history of myocardial infarction.

Serious side effects

Hives, dyspnea, asthma attacks, bronchospasm, respiratory arrest, shock, severe systemic edema accompanied by elevated blood pressure, liver failure and kidney failure, severe rash with fever, blisters, skin peeling, oral/ocular mucosal pain, altered consciousness, visual disturbances, thunderclap headache, seizures, paralysis

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid heartbeat
• elevated blood pressure
• chills
• fever
• headache

This medication should be stored in a sealed container at room temperature, ideally between 1 and 30 degrees Celsius. Proper storage maintains the medication's effectiveness and safety.

Appearance

A colorless to pale yellow transparent solution in a colorless transparent glass bottle with a rubber stopper designed for infusion.

Package unit

250 mL/bottle